Pathogenesis of mycosis fungoides and Sezary syndrome

被引:0
|
作者
Sokolowska-Wojdylo, Malgorzata [1 ,2 ]
Jankowska-Konsur, Alina [2 ,3 ]
Grzanka, Aleksandra [2 ,4 ]
Maciejewska-Radomska, Agata [1 ,2 ]
机构
[1] Gdanskiego Uniwersytetu Med, Katedra & Klin Dermatol Wenerol & Alergol, Ul Debinki 7, PL-80211 Gdansk, Poland
[2] Sekcja Chloniak Skory Polskiej Grp Badawczej Chlo, Gdansk, Poland
[3] Akad Med Wroclawiu, Katedra & Klin Dermatol Wenerol & Alergol, Wroclaw, Poland
[4] Uniwersytetu M Kopern Toruniu, Collegium Med, Katedra Klin Dermatol Chorob Przenoszonyc Droga P, Torun, Poland
来源
PRZEGLAD DERMATOLOGICZNY | 2012年 / 99卷 / 03期
关键词
cutaneous T cell lymphoma; immunology; genetics; tumour markers;
D O I
暂无
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Primary cutaneous T-cell lymphomas (CTCL) are a heterogeneous group of lymphoproliferative disorders derived from "skin-homing"lymphocytes CD4+. This phenomenon is also observed in the course of other chronic inflammatory processes in the skin, which results in significant diagnostic difficulties in CTCL, especially in the early stages of the disease. Recent studies indicate the pathogenetic complexity of CTCL. It is believed that one of the most important factors leading to the clonal proliferation of lymphocytes in the skin is its microenvironment. It has been proved that not only CLA (cutaneous leucocyte antigen) but also numerous chemokines, their receptors (CCR4, CCR10, CCL17, CCL27) and cytokines (IL-15, IL-16, IL-17, IL-21, IL-22) are involved in the process of skin infiltration. In this article we present a systematic review of current opinions on the aetiopathogenesis of mycosis fungoides and Sezary syndrome, which accounts for 75% of all primary CTCL.
引用
收藏
页码:235 / 240
页数:6
相关论文
共 50 条
  • [31] New trends in the management of mycosis fungoides and Sezary syndrome
    Batycka-Baran, Aleksandra
    Reich, Adam
    Jankowska-Konsur, Alina
    Maj, Joanna
    POSTEPY DERMATOLOGII I ALERGOLOGII, 2009, 26 (01): : 41 - 55
  • [32] Extracorporeal Photopheresis in the Treatment of Mycosis Fungoides and Sezary Syndrome
    Zic, John A.
    DERMATOLOGIC CLINICS, 2015, 33 (04) : 765 - +
  • [33] Quality of life of patients with mycosis fungoides and Sezary syndrome
    Jaeger, Manuel
    Oezistanbullu, Deniz
    Klemke, Claus-Detlev
    Tratzmiller, Sabine
    DERMATOLOGIE, 2022, 73 (10): : 759 - 764
  • [34] EORTC guidelines for the treatment of Mycosis Fungoides/Sezary Syndrome
    Knobler, R.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2006, 126 : S11 - S11
  • [35] Alemtuzumab in patients with advanced mycosis fungoides and Sezary syndrome
    Beltran-Garate, Brady
    Gomez, Henry
    Lopez, Jose L.
    Borrego, Mildred
    Prieto, Mercedes
    Carrasco-Yalan, Antonio A.
    Huamani, Julia
    Castillo, Jorge
    Da Costa, Osiris
    BLOOD, 2007, 110 (11) : 1003A - 1004A
  • [36] SEZARY SYNDROME - LEUKEMIC VARIANT OF MYCOSIS-FUNGOIDES
    LOFFLER, H
    MEYHOFER, W
    LANGE, RH
    EHLERS, G
    REMMELE, W
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 1974, 99 (10) : 429 - 434
  • [37] Remarkable Advances in the Management of Mycosis Fungoides and the Sezary Syndrome
    Hoppe, Richard T.
    ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 (05) : 242 - 243
  • [38] How We Treat Mycosis Fungoides and Sezary Syndrome
    Khan, Niloufer
    Noor, Sarah J.
    Horwitz, Steven
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (09) : 573 - 581
  • [39] CHEMOTHERAPY FOR MYCOSIS-FUNGOIDES AND THE SEZARY-SYNDROME
    ROSEN, ST
    FOSS, FM
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 1995, 9 (05) : 1109 - +
  • [40] Morphology of Mycosis Fungoides and Sezary Syndrome in Skin of Color
    Espinosa, Maria L.
    Walker, Christina J.
    Guitart, Joan
    Mhlaba, Julia M.
    CUTIS, 2022, 109 (03): : E3 - E7